Folia Pharmacologica Japonica最新文献_第4页

[The 75th Regional Meeting (Kita Area)]. [第75届区域会议（北区）]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.S24087

引用次数: 0

[Real-time measurement of neuromodulators using GRAB sensors]. [利用GRAB传感器实时测量神经调节剂]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24111

Rentaro Higuchi, Yasutaka Mukai, Hiroaki Norimoto

{"title":"[Real-time measurement of neuromodulators using GRAB sensors].","authors":"Rentaro Higuchi, Yasutaka Mukai, Hiroaki Norimoto","doi":"10.1254/fpj.24111","DOIUrl":"https://doi.org/10.1254/fpj.24111","url":null,"abstract":"To advance our understanding of the neuronal mechanisms underpinning animal behavior, it is important to integrate traditional electrophysiological methodologies with cutting-edge technologies capable of providing detailed insights into the dynamics of neuromodulators. However, achievement of high spatial and temporal resolution in neuromodulator measurements has presented significant challenges, particularly in the context of real-time observations within freely behaving animals. Recent innovations, exemplified by the development of genetically encoded fluorescent indicator, commonly referred to as \"GRAB sensors,\" have addressed these limitations. These tools enable the real-time, high-precision quantification of neuromodulators, representing a transformative advancement in the field. Notably, GRAB sensors have been designed to target a broad spectrum of neuromodulators, including dopamine (DA), acetylcholine (ACh), noradrenaline/norepinephrine (NE), and neuropeptides, offering unparalleled specificity, sensitivity, and temporal resolution. This review provides an overview of the features and advantages of GRAB sensors, highlights their diverse applications, and discusses key considerations pertinent to their implementation in contemporary neuroscience research.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 3","pages":"195-200"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Regulation of myeloid-derived suppressor cells by glutamate]. 谷氨酸对髓源性抑制细胞的调控。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25009

Masashi Tachibana

{"title":"[Regulation of myeloid-derived suppressor cells by glutamate].","authors":"Masashi Tachibana","doi":"10.1254/fpj.25009","DOIUrl":"https://doi.org/10.1254/fpj.25009","url":null,"abstract":"Myeloid-derived suppressor cells (MDSCs) suppress anti-tumor immunity in tumor bearers, which leads to tumor progression. Immune checkpoint blockers (ICBs) demonstrated significant efficiency against various cancers; however, their success rate is limited to approximately 20-30% in patients with cancer. To address this limitation, predictive biomarkers and combination therapies are required. Since MDSCs are supposed to be crucial for the resistance to ICBs, targeting MDSCs could be a promising approach for cancer immunotherapy. Granulocyte colony-stimulating factor (G-CSF), widely used as prophylaxis and therapy for febrile neutropenia (FN), has been shown to significantly reduce its incidence. However, G-CSF has been reported to promote tumor progression caused by the enhancing the proliferation of MDSCs. We found that G-CSF enhances the immunosuppressive activity of MDSCs through the upregulation of γ-glutamyltransferase 1 (GGT1). GGT1, an enzyme hydrolyzing extracellular glutathione, is reported to be a marker for early-stage cancers and promote tumor progression. It is suggested that GGT1 increases glutamate levels through glutathione hydrolysis and that metabotropic glutamate receptor signaling enhances the immunosuppressive activity of MDSCs. Moreover, in FN mouse models, we observed that G-CSF promoted tumor progression, while the inhibition of GGT abolished. Together, the inhibition of GGT can mitigate the tumor-promoting effects of MDSCs without compromising the beneficial effect of G-CSF. These insights should lead to the safer and more effective cancer immunotherapy.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 3","pages":"158-162"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The potential of neural microphysiological systems (MPS)]. [神经微生理系统（MPS）的潜力]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24098

Ikuro Suzuki

引用次数: 0

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25002

Yukio Ago

引用次数: 0

[Past history of obesity and immune memory in age-related macular degeneration]. [年龄相关性黄斑变性患者的肥胖史和免疫记忆]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24069

Masayuki Hata

引用次数: 0

[Preface]. (前言)。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24093

Yuri Kato, Yasunari Kanda

引用次数: 0

[Safety and efficacy assessments using human iPS cell-derived cardiomyocytes]. [使用人类iPS细胞衍生心肌细胞的安全性和有效性评估]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24043

Hiroyuki Kawagishi, Yasunari Kanda

{"title":"[Safety and efficacy assessments using human iPS cell-derived cardiomyocytes].","authors":"Hiroyuki Kawagishi, Yasunari Kanda","doi":"10.1254/fpj.24043","DOIUrl":"https://doi.org/10.1254/fpj.24043","url":null,"abstract":"The delay and loss of drugs are serious problems in Japan. To overcome this issue, it is important to strengthen drug development capabilities. For drug development, the establishment and advancement of non-clinical testing methods are necessary for safe and effective clinical trials. Recently, the movement toward alternatives to animal testing has accelerated internationally. New Approach Methodologies (NAMs), such as human inducible pluripotent stem cell (hiPSC) technology and in silico modeling & simulation, are considered valuable for drug development. It has been demonstrated that hiPSC-derived cardiomyocytes (hiPSC-CMs) are useful tools to assess drug-induced cardiotoxicity, including arrhythmia and cardiac contractile dysfunction, leading to the use of hiPSC-CMs in the drug review process. Advancing hiPSC technologies have enabled the generation of mature hiPSC-CMs and engineered heart tissues, which are expected to provide novel information in drug safety and efficacy evaluation. Furthermore, it would be possible to establish the non-clinical evaluation that takes into account individual differences by developing hiPSCs bearing characteristics specific to certain populations, such as pediatrics or rare disease patients. Here, we present the recent findings and future perspectives on non-clinical evaluation using hiPSC technology.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 1","pages":"4-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pharmacological and clinical profiles of belumosudil mesylate (REZUROCK_® Tablets), a selective inhibitor of ROCK2]. [选择性ROCK2抑制剂甲磺酸白莫地尔（REZUROCK®片）的药理学和临床研究概况]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24091

Yuya Nishimura, Toshiyuki Tsuchiya, Koji Kijima, Takashi Matsuhira

引用次数: 0

[Efforts to develop therapeutic agents for bacterial infections to fight against AMR (antimicrobial resistance)]. [开发细菌感染治疗剂以对抗抗生素耐药性的努力]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24082

Miki Takemura

{"title":"[Efforts to develop therapeutic agents for bacterial infections to fight against AMR (antimicrobial resistance)].","authors":"Miki Takemura","doi":"10.1254/fpj.24082","DOIUrl":"https://doi.org/10.1254/fpj.24082","url":null,"abstract":"The global spread of antimicrobial resistance (AMR) is a threat to the international community, but few new antimicrobials are in the development stage and there are few options to treat AMR infections. In light of this situation, AMR has been continuously featured on the G7 agenda since 2015, and the 2023 G7 Hiroshima Leaders' Communiqué also states that in recognition of the global and rapid spread of AMR, push and pull incentives will be explored and implemented. In addition, the World Health Assembly adopted the Global Action Plan on AMR in 2015, and Japan developed its first AMR action plan in 2016. An updated version has been released in 2023. It is hoped that the attractiveness of the antibiotic market will be improved, and the new antibiotic development will be revitalized by further expansion and enhancement of the pull incentive systems. Cefiderocol, a novel siderophore cephalosporin, demonstrates potent antibacterial activity against carbapenem-resistant Gram-negative bacteria, which are considered to be particularly high-priority pathogens by the World Health Organization (WHO) and other organizations. A partnership between the SHIONOGI, the Global Antibiotic Research and Development Partnership (GARDP) and the Clinton Health Access Initiative (CHAI) formed to improve access to cefiderocol in countries around the world, including low- and middle-income countries. In order to bring these efforts to fruition in the fight against AMR, it is important to have further understanding and cooperation from people around the world, regardless of country or field.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 3","pages":"184-190"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0